Trials / Completed
CompletedNCT02337062
Phase IIIb Study of APD421 in Combination as PONV Prophylaxis
Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,147 (actual)
- Sponsor
- Acacia Pharma Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APD421 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2015-01-13
- Last updated
- 2019-03-20
- Results posted
- 2017-08-04
Locations
25 sites across 3 countries: United States, France, Germany
Source: ClinicalTrials.gov record NCT02337062. Inclusion in this directory is not an endorsement.